Arbor Biotechnologies shining with new CRISPR enzyme
Arbor Biotechnologies is shining with its new CRISPR enzyme and has successfully bagged USD 15.6 million in series A funding. The company has recently announced its first scientific discovery of a new enzyme, Cas13d, a CRISPR-Cas13 enzyme. It could offer advantages over other enzymes including small size facilitating the packaging into the viruses used to deliver CRISPR.
Adaptimmune and GSK’s T-cells initiates responses in solid tumor patients
Adaptimmune has received fractional responses in three out of the first four round cell/ myxoid liposarcoma (MRCLS) patients treated with its T cells. Early data has elevate...
